MG
IONS icon

Meditor Group’s Ionis Pharmaceuticals IONS Stock Holding History

Meditor Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-490,000
Closed -$18.4M – 15
2013
Q3 		$18.4M Sell
490,000
-30,000
-6% -$896K 2.59% 14
2013
Q2 		$14M Buy
+520,000
New +$11.1M 1.89% 15

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Meditor Group's IONS Position: Q4 2013 in Review

Meditor Group sold out of Ionis Pharmaceuticals (IONS) in Q4 2013, closing a stake of 490,000 shares — an estimated $18.4M sold.

Meditor Group first reported a position in IONS in Q2 2013 and held it in 2 quarters. The position peaked at $18.4M in Q3 2013. 213 funds tracked by Wall St. Rank hold IONS as of Q4 2013.

  • Meditor Group reported no remaining Ionis Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Meditor Group sold 490,000 Ionis Pharmaceuticals shares in Q4 2013, an estimated $18.4M.
  • Meditor Group first reported a position in Ionis Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Meditor Group's Ionis Pharmaceuticals position peaked at $18.4M in Q3 2013.
  • 213 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2013.

Based on Meditor Group's 13F filing for Q4 2013, filed 21 Jan 2014.